|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
While p53 mutations and MDM2 amplification have been reported to occur in rhabdomyosarcoma and osteogenic sarcoma, the incidence of MDM2 in other pediatric solid tumors is not known.
|
8261417 |
1993 |
|
Osteosarcoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
While p53 and Rb inactivation occurs in most osteosarcomas, the landscape of associated driver mutations has proved extensive.
|
29435436 |
2018 |
|
Osteosarcoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Whereas, overexpression of microRNA‑152 targets DKK1 to inhibit cell proliferation, induce apoptosis, and promote LDH activity, caspase-3/9 activities and Bax/Bcl-2 and p53 protein expression levels of osteosarcoma through inactivation of the Wnt/β-catenin signaling pathway.
|
29845282 |
2018 |
|
Osteosarcoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Western blot was conducted to detect the expression of p53 after the knockdown of SNHG7 in osteosarcoma cells.
|
31114984 |
2019 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
We used human osteosarcoma Saos-LP12 cells, in which wild type (wt) p53 protein was induced by treatment with isopopyl-beta-D-thiogalactopyranoside.
|
9175647 |
1997 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
We show that overexpression of the gene encoding wild-type p53 blocks the growth of osteosarcoma cells.
|
2233717 |
1990 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
We show that Notch activation combined with loss of p53 synergistically accelerates OS development in mice, although p53-driven OS is not Rbpj dependent, which demonstrates a dual dominance of the Notch oncogene and p53 mutation in the development of OS.
|
25203324 |
2014 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
We show that in hamster (Chinese hamster ovary) or human (osteosarcoma 143) cell lines the replication of both Py and papillomavirus origins was efficiently blocked by p53.
|
10775606 |
2000 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
We investigated the relationship between p53 status and the development of resistance to cisplatin in osteosarcoma cell lines.
|
10697522 |
2000 |
|
Osteosarcoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
We investigated the anti-osteosarcoma activity of IAP antagonists (also known as Smac mimetics) using cells from primary and metastatic osteosarcomas that arose spontaneously in mice engineered to lack p53 and Rb expression in osteoblast-derived cells.
|
27129149 |
2016 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
We here demonstrate that the cell cycle was arrested in G2/M phase following supplementation with DZQ of human osteosarcoma Saos-2 cells (lacking both p53 and pRb) and HCT116 cells.
|
9586815 |
1998 |
|
Osteosarcoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
We have also demonstrated that the knock-out or inhibition of mutant TP53 decreased the expression of the oncogene IGF-1R, anti-apoptotic proteins Bcl-2, and Survivin in osteosarcoma cells.
|
30667081 |
2019 |
|
Osteosarcoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
We found that the HDMX-S/HDMX-FL ratio associated with common somatic genetic lesions connected with p53 inhibition, such as p53 mutation and HDM2 overexpression in osteosarcoma cell lines.
|
22700878 |
2012 |
|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We demonstrated a germline p53 replication error in two generations of a Li-Fraumeni family affected with liposarcoma, adrenocortical carcinoma, and osteosarcoma.
|
7614454 |
1995 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
We compared ceramide levels before and after DNA damage in human osteosarcoma (U2OS) and colon cancer (HCT116) cells that were either expressing or deficient in p53.
|
22349266 |
2012 |
|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We and others have previously described murine models of osteosarcoma based on osteoblast-restricted Cre:lox deletion of Trp53 (p53) and Rb1 (Rb), resulting in a phenotype most similar to fibroblastic osteosarcoma in humans.
|
23486187 |
2013 |
|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Transfection of mutant p53 (R175H) to p53-null osteosarcoma Saos-2 cells suppressed apoptosis induced by doxorubicin (DOX), cisplatin and gamma radiation.
|
15578696 |
2005 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Topological analysis of the OSM identified 11 genes, including APP, APPBP2, ATXN1, HSP90B1, IKZF1, KRTAP10-1, PAK1, PDPK1, SMAD4, SUZ12 and TP53 as potential diagnostic biomarkers for osteosarcoma.
|
30210606 |
2018 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
To investigate the biological significance of RB and p53 gene inactivations, a wild-type RB or p53 cDNA expression vector regulated by tetracycline was introduced by stable transfection into an osteosarcoma cell line Saos-2, in which both the RB and p53 genes were inactivated.
|
9136982 |
1997 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
To discover genes that cooperate with p53 deficiency in osteosarcoma formation, we have integrated array comparative genomic hybridization, microarray expression analyses in mouse and human osteosarcomas, and functional assays.
|
19276372 |
2009 |
|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
To determine the relation between COPS3 amplification, P53 mutation, and patient outcome in osteosarcoma, tumors from a large cohort of patients with high-grade osteosarcoma and long-term clinical follow-up were examined.
|
17366602 |
2007 |
|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
To better probe the p53 response, SJSA cells (shCDK19 versus shCTRL) were treated with the p53 activator nutlin-3.
|
28416637 |
2017 |
|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
To analyze the genetic and epigenetic alterations affecting the RB1, TP53, p16INK4, and p21WAF1 tumor suppressor genes, loss of heterozygosity (LOH) at 3q and 18q, and the clinical variables of a series of Spanish children with osteosarcoma.
|
12759621 |
2003 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
To address this issue in osteosarcomas, we examined the status of E2F1 relative to cell proliferation and apoptosis in a clinical setting of human primary osteosarcomas and in E2F1-inducible osteosarcoma cell line models that are wild-type and deficient for p53.
|
19541929 |
2009 |
|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Thus, in mouse tumors with high frequency of p53 LOH (osteosarcomas and fibrosarcomas), we find that mutant p53 protein is stabilized (16/17 cases, 94%) and tumor onset is significantly accelerated compared with p53+/- tumors (GOF).
|
28277540 |
2017 |